November 28, 2011

Sanofi scoops Corporate Responsibility Award at Pharmaceutical Marketing Excellence Awards 2011 for second successive year

At the Pharmaceutical Marketing Excellence Awards ceremony in London last week, leading pharmaceutical company Sanofi was presented with the Corporate Responsibility Award for the second successive year. The Award recognises pharmaceutical companies that have demonstrated an outstanding contribution to society through responsible marketing activities.

• Download the Press Release Dated November 28, 2011 (PDF, 155Kb)

November 01, 2011

Connecting Nurses - The Care Challenge Initiative

Nursing recognition campaign to make caring ideas a reality

• Click here for more information

June 30, 2011

Sanofi Patient Group Bursary Winners Announced: Breakthrough Breast Cancer & The MS Trust Awarded £50,000

Sanofi is delighted to announce the winners of the Sanofi Patient Group Bursary scheme - Breakthrough Breast Cancer and the Multiple Sclerosis (MS) Trust will each receive a grant of £25,000 to support their initiatives, both judges to be exemplary in their respective fields.

• Download the Press Release Dated June 30, 2011 (PDF, 63Kb)

March 28, 2011

Sanofi Strengthens Support for Patient Groups with Launch of Patient Group Bursary

Sanofi-aventis has signalled a strengthening of its support for patient groups in the UK with the launch of a new Patient Group Bursary. With the NHS in England set to undergo major structural and cultural change through the implementation of the Government's far-reaching healthcare plans, the company firmly believes that patient groups will have a more important role than ever before in championing the needs of individual patients and improving the quality of their care.

• Download the Press Release Dated March 24, 2011 (PDF, 183Kb)

March 20, 2011

Jevtana® (cabazitaxel) Approved by European Commission for Treatment of Advanced Second-line Prostate Cancer

Sanofi-aventis announced today it has received marketing authorisation from the European Commission for JEVTANA® (cabazitaxel) in combination with prednisone/prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen.

• Download the Press Release Dated March 20, 2011 (PDF, 57Kb)

March 16, 2011

Sanofi-aventis appoints Dr. Richard Klausner as Chairman of the Strategic Development and Scientific Advisory Council

Sanofi-aventis is pleased to announce the appointment of Dr. Richard Klausner to Chairman of the Strategic Development and Scientific Advisory Council (SDSAC), effective March 1, 2011.

• Download the Press Release Dated March 16, 2011 (PDF, 63Kb)

March 10, 2011

Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).

• Download the Press Release Dated March 10, 2011 (PDF, 35Kb)

January 21, 2011

Jevtana® (cabazitaxel) for Prostate Cancer Recommended for Approval in the European Union

Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending to grant a marketing authorisation in the European Union for Jevtana® (cabazitaxel - 60mg concentrate and solvent for solution for infusion) in combination with prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.

• Download the Press Release Dated January 21, 2011 (PDF, 56Kb)